8-K

pf17591936-8k.htm

CURRENT REPORT

pf17591936-8k.htm

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of

report (Date of earliest event reported): October 30, 2009

PFIZER

INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State

or other jurisdiction of incorporation)

(Commission

File (Number)

(I.R.S.

Employer Identification No.)

235

East 42nd Street

10017

New

York, New York

(Address of principal executive offices)

(Zip

Code)

Registrant's

telephone number, including area code:

(212)

733-2323

Not

Applicable

(Former

Name or Former Address, if changed since last report)

Check the

appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the obligation of the registrant under any of the following provisions

(see General Instruction A.2. below):

[]

Written communication pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

[]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

[]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

(17 CFR 240.14d-2 (b))

[]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

(17 CFR 240.13e-4(c))

Item

8.01. Other Events.

On

October 16, 2009, Pfizer Inc. ("Pfizer") commenced a consent solicitation to

seek consent from the holders of Wyeth s 6.700% Notes due 2011 (CUSIP No.

026609AM); 6.700% Notes due 2011 (CUSIP No. 026609AJ); 5.250% Notes due 2013

(CUSIP No. 983024AA); 5.500% Notes due 2014 (CUSIP No. 983024AE); 5.500% Notes

due 2016 (CUSIP No. 983024AJ); 5.450% Notes due 2017 (CUSIP No. 983024AM);

7.250% Notes due 2023 (CUSIP No. 026609AC); 6.450% Notes due 2024 (CUSIP No.

983024AF); 6.500% Notes due 2034 (CUSIP No. 983024AG); 6.000% Notes due 2036

(CUSIP No. 983024AL); and 5.950% Notes due 2037 (CUSIP No. 983024AN)

(collectively, the Securities ), to amend certain provisions of the Indenture,

dated April 10, 1992, by and among Wyeth, as successor to American Home Products

Corporation and The Bank of New York Mellon ( Trustee ), as successor to

Manufacturers Hanover Trust Company, as trustee, as amended (the

Indenture ).

On

October 30, 2009, Pfizer announced that it had received consent from at least a

majority in aggregate principal amount of Securities outstanding (the Required

Consents ). As a result of Pfizer s receipt of the Required Consents,

Pfizer entered into the Eighth Supplemental Indenture ( Eighth Supplemental

Indenture ), dated as of October 30, 2009, among Wyeth, Pfizer and the

Trustee. The Eighth Supplemental Indenture is attached as Exhibit 4.1

hereto and incorporated by reference herein. Pursuant to the Eighth

Supplemental Indenture, (i) Pfizer issued an unconditional and irrevocable

guarantee (the Pfizer Guarantee ) of the prompt payment, when due, of any

amount owed to the holders of the Securities and (ii) certain provisions of the

Indenture related to (a) the consolidation or merger of Wyeth or the sale of all

or substantially all of Wyeth s assets; (b) the limitation on Wyeth s incurrence

of liens; (c) the limitation on sale and leaseback transactions by Wyeth; (d)

Wyeth s obligation to publish certain notices in Luxembourg; (e) the cure period

in connection with a default in the payment of interest with respect to the

Securities; (f) the annual date prior to which Wyeth must deliver a compliance

certificate to the Trustee; and (g) Wyeth s obligation pursuant to the Indenture

to file certain SEC reports with the Trustee, were amended.

A copy of

the press release is attached as Exhibit 99.1 hereto and incorporated by

reference herein.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits

Exhibits

Description

4.1

Eighth

Supplemental Indenture, dated October 30, 2009, among Wyeth, Pfizer and

The Bank of New York Mellon.

5.1

Opinion

of Gene A. Capello, Assistant General Counsel and Assistant Secretary of

Pfizer.

23.1

Consent

of Gene A. Capello, Assistant General Counsel and Assistant Secretary of

Pfizer (included in Exhibit 5.1).

99.1

Press

release of Pfizer dated October 30, 2009 announcing the completion of the

acquisition of Wyeth.

SIGNATURE

Under the

requirements of the Securities Exchange Act of 1934, the registrant has caused

this report to be signed on its behalf by the authorized

undersigned.

PFIZER

INC.

By:

/s/ Matthew

Lepore

Name:

Matthew

Lepore

Title:

Vice

President, Chief Counsel-Corporate Governance, and Assistant General

Counsel

Dated:

November 3, 2009

EXHIBIT

INDEX

Exhibit No.

Description

4.1

Eighth

Supplemental Indenture, dated October 30, 2009, among Wyeth, Pfizer and

The Bank of New York Mellon.

5.1

Opinion

of Gene A. Capello, Assistant General Counsel and Assistant Secretary of

Pfizer.

23.1

Consent

of Gene A. Capello, Assistant General Counsel and Assistant Secretary of

Pfizer (included in Exhibit 5.1).

99.1

Press

release of Pfizer dated October 30, 2009 announcing the completion of the

acquisition of Wyeth.